Effects of multicomponent training on lean and bone mass in postmenopausal and older women: a systematic review
Menopause. 2018 Mar;25(3):346-356. doi:10.1097/GME.0000000000000975 Marín-Cascales E, Alcaraz PE, Ramos-Campo DJ, Rubio-Arias JA.
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
PLoS One. 2018 Mar 15;13(3):e0193846. doi: 10.1371/journal.pone.0193846. eCollection 2018. PubMed PMID: 29543887; PubMed Central PMCID: PMC5854344. Iseri K, Iyoda M, Watanabe M, Matsumoto K, Sanada D, Inoue T, Tachibana S, Shibata T.
Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
J Bone Miner Metab. 2018 Mar 8. doi: 10.1007/s00774-018-0917-0. [Epub ahead of print] PubMed PMID: 29520506. Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
Combination therapy of anabolic agents and bisphosphonates on bone mineral density in patients with osteoporosis: a meta-analysis of randomised controlled trials.
BMJ Open. 2018 Mar 1;8(3):e015187. doi: 10.1136/bmjopen-2016-015187. PubMed PMID: 29500198; PubMed Central PMCID: PMC5855398. Lou S, Lv H, Li Z, Zhang L, Tang P.
MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
Eur J Endocrinol. 2018 Mar;178(3):R81-R87. doi: 10.1530/EJE-17-1002. Epub 2018 Jan 16. Review. PubMed PMID: 29339529. Adler RA.
Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis.
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1206-1213. doi: 10.1210/jc.2017-02406. PubMed PMID: 29309589. Anastasilakis AD, Makras P, Pikilidou M, Tournis S, Makris K, Bisbinas I, Tsave O, Yovos JG, Yavropoulou MP.
Denosumab: A Review in Postmenopausal Osteoporosis. Drugs Aging.
2018 Feb;35(2):163-173. doi: 10.1007/s40266-018-0525-7. Erratum in: Drugs Aging. 2018 Mar 9;:. PubMed PMID: 29435849. Deeks ED. https://www.ncbi.nlm.nih.gov/pubmed/29435849
Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
J Bone Miner Metab. 2018 Mar;36(2):221-228. doi: 10.1007/s00774-017-0829-4. Epub 2017 Mar 14. PubMed PMID: 28293779. Nakatoh S.
The Quest for Osteoporosis Mechanisms and Rational Therapies: How Far We’ve Come, How Much Further We Need to Go.
J Bone Miner Res. 2018 Mar;33(3):371-385. doi: 10.1002/jbmr.3400. Epub 2018 Feb 22. PubMed PMID: 29405383. Manolagas SC.
Denosumab mid-term densitometric gain in postmenopausal osteoporosis women in clinical practice: comment on “Variability of denosumab densitometric response in postmenopausal osteoporosis.
Rheumatol Int. 2018 Jun;38(6):1161-1162. doi: 10.1007/s00296-018-4007-3. Torrente-Segarra V, Roig-Vilaseca D.
